Company Encyclopedia
View More
name
Silo Pharma
SILO.US
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations.
1.925 T
SILO.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking332/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-86.11%E
    • Profit Margin-7041.12%E
    • Gross Margin-14.77%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-34.18%D
    • Total Assets YoY-25.47%E
    • Net Assets YoY-26.15%E
  • Cash ScoreC
    • Cash Flow Margin-1.42%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio21.55%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 | SILO Stock News

    Silo Pharma, Inc. has signed a non-binding Letter of Intent with Allucent to support Phase 1 clinical studies of its SPC-15 nasal spray, aimed at treating PTSD and anxiety. The studies will include an Open-Label, Single Ascending Dose (SAD) and an Open-Label, Multiple Ascending Dose (MAD) study. The collaboration is expected to enhance the efficiency of generating safety and pharmacokinetic data. SPC-15 is a serotonin 5-HT4 receptor agonist in preclinical development, with a focus on fast brain action delivery.

    StockTitan·
    US
    SILO
    +5.92%
    StockTitan·
    US
    SILO
    +5.92%

    Silo Pharma Faces Potential Nasdaq Delisting Over Minimum Bid Price Compliance

    Silo Pharma Inc. is at risk of being delisted from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted an extension until June 22, 2026, to meet this requirement. If the stock does not close at or above $1.00 for 10 consecutive business days by the deadline, delisting may occur. Silo Pharma is considering a reverse stock split as a potential measure to regain compliance.

    Reuters·
    US
    SILO
    +5.92%
    Reuters·
    US
    SILO
    +5.92%

    Chmn Weisblum Buys 5,000 ($2.1K) Of Silo Pharma Inc [SILO]

    Weisblum Eric Chairman of the Board of Silo Pharma Inc [SILO] filed a Form 4 on December 16, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/15/25TransactionPurchaseShares5,000Price$0.42Value$2,075Ending Holdings: 216,932 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    SILO
    +5.92%
    Reuters·
    US
    SILO
    +5.92%

    Silo Pharma CEO Eric Weisblum Acquires Common Shares

    Eric Weisblum, CEO of Silo Pharma Inc., has acquired common shares of the company. This information was originally published by Silo Pharma via the EDGAR system of the U.S. Securities and Exchange Commission. The news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SILO
    +5.92%
    Reuters·
    US
    SILO
    +5.92%

    Silo Pharma CEO Eric Weisblum Reports Acquisition of Common Shares

    Eric Weisblum, CEO of Silo Pharma Inc., reported acquiring common shares of the company. The full filing is available via EDGAR, the SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SILO
    +5.92%
    Reuters·
    US
    SILO
    +5.92%
    © 2025 Longbridge｜Disclaimer